Chebib FT, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies. Kidney Med. 2023 Jun;5(6):100639. doi: 10.1016/j.xkme.2023.100639
Du XL, Parikh RC, Lairson DR, Giordano SH, Cen P. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Med Oncol. 2013 Mar;30(1):440. doi: 10.1007/s12032-012-0440-4
Codony-Servat J, Garcia-Albeniz X, Pericay C, Alonso V, Escudero P, Fernandez-Martos C, Gallego R, Martinez-Cardus A, Martinez-Balibrea E, Maurel J. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer. Med Oncol. 2013 Mar;30(1):428. doi: 10.1007/s12032-012-0428-0
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.
Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.